Bristol Myers Squibb exceeds revenue expectations and raises guidance for 2025

From Yahoo Finance: 2025-04-24 11:55:00

Bristol Myers Squibb reported first-quarter 2025 revenues of $11.20 billion, surpassing the consensus of $10.70 billion. Sales decreased 6% year-over-year, with U.S. revenues of $7.9 billion down by 7%. International revenues of $3.3 billion decreased by 2% or increased by 2% Ex-FX. Growth Portfolio revenues reached $5.6 billion, up 16% on a reported basis, driven by Opdivo, Breyanzi, Reblozyl, and Camzyos. Sales of Opdivo increased 9% to $2.265 billion. Adjusted EPS was $1.80, beating the consensus of $1.49. Bristol Myers Squibb raised its fiscal year 2025 adjusted EPS guidance from $6.55-$6.85 to $6.70-$7.00.

In addition, the company raised its 2025 sales guidance from $45.50 billion to $45.80 billion—$46.80 billion, compared to the consensus of $45.76 billion. The increased guidance reflects the strong performance of the Growth Portfolio and better-than-expected Legacy Portfolio sales in the first quarter. BMY stock is down 0.54% at $48.27.



Read more at Yahoo Finance: Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact